Internal bleeding higher with popular heart device than earlier model

The incidence of internal bleeding was higher in the most commonly implanted heart device than in an earlier model, according to two studies at Henry Ford Hospital in Detroit.

The HeartMate II, a (LVAD) is a continuous-flow mechanical pump connected to the patient's heart that takes over the pumping of the weakened heart's left ventricle.

"Although there were more instances of bleeding in the skull and gastrointestinal track with the HeartMate II, as opposed to the earlier model, there was no increase in ," says lead author Jeffrey A. Morgan, M.D., associate director of Mechanical Circulatory Support in the Edith and Benson Ford Heart &Vascular Institute at Henry Ford.

Dr. Morgan will present the studies on June 11 at the annual conference of the American Society of Artificial Internal Organs in Washington, D.C.

From March 2006 through May 2010, 64 patients with chronic underwent implantation of a HeartMate II LVAD as a bridge to transplant or a permanent therapy for those ineligible for transplants.

The incidence of gastrointestinal bleeding or adverse neurological events (ANE) was evaluated to determine their impact on survival and identify predictors of occurrence.

The overall incidence of gastrointestinal bleeding was nearly 22 percent, and the incidence of major ANEs was eight percent. Patients with an ANE were significantly older, with a higher incidence of chronic renal insufficiency. They also had higher International Normalized Ratios (INRs), a lab test that measures the time it takes for blood to clot, and compares it to an average, at the time of the event. The higher the INR, the longer it takes blood to clot.

No complications due to blood clots occurred in those with , but for patients with an ANE, there were four intracranial hemorrhages and one thromboembolic stroke.

There was no significant difference in gender, race, cause of heart failure, diabetes, or body mass index (BMI) between patients who had post-operative bleeding and those who did not.

Study co-author Robert J. Brewer, M.D., surgical director of the Program at Henry Ford, believes that as data accumulates on the relatively low incidence of thromboembolic events with the HeartMate II for patients on low-dose or no anticoagulation, it may be prudent to lower the goal INR, with the intent of lowering bleeding complications.

The HeartMate II is smaller, with fewer moving parts, than the previous model, the HeartMate I XVE, and requires less invasive surgery. Its size makes it available to a larger number of advanced-stage heart failure patients, and it has been predicted to greatly increase patients' quality of life. The device can cover the full output of a healthy heart. Studies have shown that continuous-flow pumps last much longer than pulsing pumps before they must be replaced.

Usage of LVADs has increased in the United States, where heart failure affects five million people, but there are less than 3,000 donor organs available annually worldwide. Last year, nearly 2500 patients were implanted with the device in the United States, which is used chiefly for those waiting for a heart transplant due to the chronic donor shortage. In other cases, it is used for long-term support in patients who are not candidates for a transplant.

Related Stories

Study: Fewer infections with new heart-pump implant

May 27, 2010

A state-of-the-art heart pump recently approved for use in end-stage cardiac patients has a significantly lower risk for infection than an earlier model of the device, according to researchers at Henry Ford Hospital in Detroit.

New patient guidelines for heart devices

Apr 17, 2011

A series of new guidelines for cardiac specialists has been developed to determine when heart failure patients should receive a mechanical heart-pumping device.

Recommended for you

Adrenal sex hormone level may predict heart disease risk

7 hours ago

(HealthDay)—Blood levels of the adrenal sex hormone dehydroepiandrosterone (DHEA) and its sulfate (DHEA-S) may predict an increased risk of coronary heart disease (CHD) in elderly men, according to a study ...

Researchers aim to simplify life saving drug

Oct 29, 2014

Heparin, the life saving blood thinner used in major surgeries and treatment of heart diseases, is a complicated drug but a research team from the University of British Columbia has set out to make its use a lot safer by ...

Frequent readmissions, high costs after cardiac arrest

Oct 29, 2014

(HealthDay)—Frequent readmissions and high inpatient costs are seen among older survivors of in-hospital cardiac arrest, according to a study published online Oct. 28 in Circulation: Cardiovascular Quality an ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.